Talquetamab Combos Show Survival Benefit in r/r Myeloma

Published Date: 17 Jun 2026

Interim findings from the phase 3 MonumenTAL-3 trial highlight overall and progression-free survival as well as response rates compared with standard therapy.

Read Full News

Latest News

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

In high-risk low-grade glioma, starting with temozolomide or radiotherapy yields similar survival.

Stem Cell Transplant Associated With Better PFS in NKTCL

Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events

A lung cancer trial was stopped early due to a high rate of fatal adverse events with the addition of thoracic radiotherapy to standard maintenance immunotherapy.

Smoldering Myeloma: The Treatment Issue Is Getting Trickier

An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Todays Updates

Palliative Care Remains Uncommon in Young Adults With Cancer

Concurrent palliative care use among young adults with advanced cancer is less than 20%, with substantial variation across cancer types.

Todays Updates

Palliative Care Remains Uncommon in Young Adults With Cancer

Concurrent palliative care use among young adults with advanced cancer is less than 20%, with substantial variation across cancer types.

Latest News

In high-risk low-grade glioma, starting with temozolomide or radiotherapy yields similar survival.

Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.

A lung cancer trial was stopped early due to a high rate of fatal adverse events with the addition of thoracic radiotherapy to standard maintenance immunotherapy.

An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

The newly approved inhibitor is for patients who previously received another drug of the same class.

News All Time

FDA Approves Subcutaneous Isatuximab for MM Indications

The drug can now be administered with the hands-free automated CirCLIQ on-body injector.

AI-Driven Biomarker Predicts Prostate Cancer Outcomes

The tool, based on histology only, may help identify patients most likely to benefit from triplet therapy.

Community Oncology Well Suited for Advanced Cancer Patients

Experts tout common characteristics of local physician practices that are beneficial to those with advanced disease.

Real-World EV Plus Pembro Success Seen in Urothelial Cancer

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

Germline Variants Predict Lobular Breast Cancer Recurrence

For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.

MRI Enhancement Predicts Breast Cancer in BRCA Carriers

Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.

Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL

Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.

Breast Cancer Incidence Rises in Asian American Women

A cross-sectional population-based study examines trends in invasive breast cancer incidence rates in Asian American, Native Hawaiian, and Pacific Islander ethnic groups.

Asian Women With Breast Cancer Outlive White Peers

Researchers seek to understand why Asian women fare better with the disease.

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

By carefully controlling the mix of stem and T cells, Orca‑T lowers the risk for graft-vs-host disease in adults with hematologic cancers.

Combined Models With AI Improve Breast Cancer Prediction

Combining mammography AI, polygenic, and clinical risk models improves 10-year breast cancer risk prediction compared with any single model.

Induction Immunotherapy Has Durable Survival Benefit in LACC

Patients with locally advanced cervical cancer who receive dual checkpoint blockade before standard chemoradiation have high 3-year survival, but outcomes are poorer for those with ‘cold’ tumors.

Time to Rethink Maintenance Pemetrexed in NSCLC?

For patients with advanced non-small cell lung cancer (NSCLC), adding pemetrexed to maintenance pembrolizumab may only increase toxicity, not survival.

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

Drug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.

CAR T Cells Produce 10-Year Remissions in Some With Lymphoma

Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Recommended News For You

A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.

Housing aid linked to lower medical financial hardship among US renters with cancer

The Early Progression of Prostate Cancer Is Not Stopped by Metformin.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients

A small rise in cancer was observed following the 1986 Chernobyl accident.

Number of cancer survivors in the US reaches 18.6 million—projected to exceed 22 million by 2035

Recommended Articles For You

Exploring New Solutions for MCV Low: Unlocking the Potential for Improved Health 

Multi-Omic Rejuvenation of Aged Tissues With Transient Reprogramming and Its Therapeutic Potential 

Unlocking the Secret to Accurate ANC Calculation with This Informative Blog Post 

A New Hope: Exploring the Potential of Pegaspargase in Treating Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More men with prostate cancer are avoiding unnecessary surgery

2.

Even when they are not paying attention, children are still learning.

3.

FDA Approves New Bladder Cancer First-Line Standard of Care.

4.

"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.

5.

AI is useful in low-resource areas for triaging breast masses.

1.

Community Cancer Awareness Through Survivor Advocacy Networks

2.

Evidence-Based Pathways for Survivorship Care Planning

3.

Red Blood Cell Aging and Clinical Implications

4.

Understanding Phyllodes Tumor: Symptoms, Diagnosis, and Treatment Options

5.

Clinical Trends in Oncology in Clinical Decision-Making

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Navigating the Complexities of Ph Negative ALL - Part VI

2.

Efficient Management of First line ALK-rearranged NSCLC - Part V

3.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

4.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion

5.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot